Salbutamol dry-powder inhalation - Sofotec

Drug Profile

Salbutamol dry-powder inhalation - Sofotec

Alternative Names: Albuterol dry-powder inhalation - Sofotec; Novolizer Salbutamol; Salbutamol Novolizer

Latest Information Update: 07 Nov 2003

Price : $50

At a glance

  • Originator Sofotec
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 07 Nov 2003 Salbutamol 100µg Novolizer is available for licensing outside Germany and major West European countries (http://www.viatris.com/)
  • 01 Nov 2001 Launched for Asthma in Germany (Inhalation,Powder)
  • 30 Nov 1999 Registered for Asthma in Germany (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top